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Background-—Rehospitalizations (RHs) after ST-elevation myocardial infarction carry a high economic burden and may deteriorate
quality of life. Characterizing patients at higher risk may allow the design of preventive measures. We studied the frequency,
reasons, and predictors for unplanned cardiac and noncardiac RHs in ST-elevation myocardial infarction patients undergoing
primary percutaneous coronary intervention.
Methods and Results-—In this post-hoc analysis of the COMFORTABLE AMI (Comparison of Biolimus Eluted From an Erodible Stent
Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction; NCT00962416) trial including 1137 patients,
unplanned cardiac and noncardiac RHs occurred in 133 (11.7%) and in 79 patients (6.9%), respectively, at 1 year. The most
frequent reasons for unplanned cardiac RHs were recurrent chest pain without evidence of ischemia (20.4%), recurrent chest pain
with ischemia and coronary intervention (16.9%), and ischemic events (16.9%). Unplanned noncardiac RHs occurred most
frequently attributed to bleeding (24.5%), infections (14.3%), and cancer (9.1%). On multivariate analysis, left ventricular ejection
fraction (22% increase in the rate of RHs per 10% decrease; P=0.03) and angiographic myocardial infarction Syntax score (34%
increase per 10-point increase; P=0.01) were independent predictors of unplanned cardiac RHs. Age emerged as the only
independent predictor of unplanned noncardiac RHs. Regional differences for unplanned cardiac RHs were observed.
Conclusions-—Among ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention in the
setting of a randomized, clinical trial, unplanned cardiac RHs occurred in 12% with recurrent chest pain being the foremost reason.
Unplanned noncardiac RHs occurred in 7% with bleeding as the leading cause. Left ventricular ejection fraction and Syntax score
were independent predictors of unplanned cardiac RHs and identiﬁed patient subgroups in need for improved secondary
prevention.
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R ehospitalizations (RHs) after myocardial infarction (MI)are the aftermath of in-hospital quality of care, postdis-
charge management, and an individual’s vulnerability.1,2 Up to
one ﬁfth of patients who survive to hospital discharge will be
readmitted within 1 month,3,4 with the consequent economic
burden as well as impact on quality of life and long-term
prognosis. Identifying the characteristics associated with RHs
could aid in stratifying patients according to their risk of RHs
and assist physicians in optimizing management following
discharge.5
Although extensive data have been published regarding
RHs after acute MI,5 RHs after primary percutaneous coronary
intervention (PCI) in patients presenting with ST-segment
elevation MI (STEMI) have not been systematically studied,
and available data are limited to 30 days of follow-up.2,4
Moreover, predictors of RHs have not been consistent
throughout studies, which is partially explained by the diverse
types of RHs reported (eg, all cause, cardiac related), as well
as the quality and granularity of data expected based on the
study design.5 In addition, regional differences in the
frequency emerged in multinational studies, underscoring
the impact of health systems and local practices on RHs.2
Planned RHs post-PCI for STEMI may reﬂect good clinical
practice, given that they relate to clinical decisions to better
diagnose or treat patients. Such decisions could occur before
(eg, hip replacement), during (eg, staged PCI), or after (eg,
implantation of a cardioverter deﬁbrillator) the index hospi-
talization. Consequently, examining unplanned RHs may
better characterize patients at increased risk. Our aim was
to investigate the frequency, reasons, and predictors of
unplanned cardiac and noncardiac RHs following primary PCI
in STEMI patients.
Methods
Study Design and Patient Population
We performed a post-hoc analysis of data from the
COMFORTABLE AMI trial (Comparison of Biolimus Eluted
From an Erodible Stent Coating With Bare Metal Stents in
Acute ST-Elevation Myocardial Infarction; NCT00962416). The
study design has been published elsewhere.6 In brief, this was
a multicenter, randomized, assessor-blinded, superiority trial,
in which 1161 STEMI patients undergoing primary PCI at 11
sites in 5 countries in Europe and Israel between September
19, 2009 and January 25, 2011 were assigned to a biolimus
drug-eluting stent (BioMatrix; Biosensors Europe SA, Morges,
Switzerland) or to a bare metal stent (Gazelle; Biosensors
Europe SA, Morges, Switzerland).
Patients were eligible for randomization if they were aged
18 years or older with symptom onset within 24 hours,
electrocardiographic criteria for STEMI, and angiographic
evidence of at least 1 culprit lesion within the infarct vessel.
There were no limits regarding the number of treated lesions,
vessels, or complexity. Exclusion criteria were the presence of
mechanical complications of acute MI, known allergy to any
study medication, use of vitamin K antagonists, planned
surgery unless dual antiplatelet therapy could be maintained
during the perisurgical period, history of bleeding diathesis or
known coagulopathy, pregnancy, participation in another trial
before reaching the primary end point, inability to provide
informed consent, and noncardiac comorbid conditions with
life expectancy of less than 1 year.
For the purpose of the current analysis, all randomized,
controlled trial participants were included, except for patients
not surviving index hospitalization, or presenting with out-of-
hospital death as ﬁrst event at follow-up. The study complied
with the Declaration of Helsinki and was approved by the
institutional ethics committee at each participating hospital.
All patients included provided written informed consent.
Procedures
After randomization, all patients were treated according to
current guidelines and the following co-interventions were
indicated: (1) Thrombus aspiration was recommended in all
patients whenever aspiration was deemed technically
Clinical Perspective
What is New?
• Among patients undergoing percutaneous coronary inter-
vention for ST-elevation myocardial infarction, unplanned
cardiac rehospitalizations at 1 year occurred in 12%,
representing approximately two thirds of all unplanned
rehospitalizations.
• The most common reason for unplanned cardiac rehospi-
talizations was recurrent chest pain, which was categorized
by treating physicians as noncoronary in one third of cases.
• Syntax myocardial infarction score and left ventricular
ejection fraction were independent predictors of unplanned
cardiac rehospitalizations at 1 year.
• Unplanned noncardiac rehospitalizations at 1 year occurred
in 7% of patients with bleeding as the leading cause and age
emerging as the only independent predictor identiﬁed.
What are the Clinical Implications?
• Myocardial infarction Syntax score and predischarge ejec-
tion fraction assessment may help in identifying patients at
increased risk for unplanned cardiac rehospitalizations and
who could beneﬁt from closer monitoring after percuta-
neous coronary intervention for ST-elevation myocardial
infarction.
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feasible; (2) complete revascularization of all lesions within
the infarct vessel had to be performed with the randomly
allocated study stent; and (3) nonculprit vessels were treated
by default by biolimus-eluting stent at baseline and during
follow-up.
Acetylsalicylic acid (≥250 mg) was administered before the
procedure. In the absence of contraindications, patients
received an initial dose of prasugrel 60 mg (including patients
preloaded with clopidogrel) followed by a daily dose of 10 mg.
When prasugrel was contraindicated, clopidogrel was admin-
istered at a loading dose of 600 mg, followed by a dose of
75 mg twice-daily for 7 days, followed by a maintenance dose
of 75 mg once-daily. Dual antiplatelet therapy was prescribed
for the duration of at least 1 year in all patients.
Data Collection
All RHs were prospectively collected by dedicated research
personnel in the frame of the trial’s severe adverse event
reporting process throughout 2 years. Paper forms were
centrally collected and entered into a dedicated database
(Cardiobase, Clinical Trials Unit, and Department of Cardiol-
ogy, Bern University Hospital, Bern, Switzerland).
Study End Point Deﬁnitions
RHs were deﬁned as any visit to the emergency department
for more than 6 hours or any hospital admission. Unplanned
RHs were deﬁned as unscheduled visits. In all instances, the
main reasons for RH were ascertained in predeﬁned cate-
gories (see Table S1 and Table 1). Two investigators (E.S.,
M.F.) reviewed independently all severe adverse events and
adjudicated RHs. Disagreements were adjudicated by a third
investigator (L.R.). When several factors contributed to RHs,
all were adjudicated, and a predeﬁned study-speciﬁc hierar-
chical rule was used to assign the main reason of RH (see
Tables S2 and S3). MI Syntax score was determined as
previously described in detail.7 Recurrent ischemic events
were deﬁned according to the previously published study
protocol.6 Recurrent chest pain and ischemia with or without
intervention was deﬁned as chest pain attributed to angio-
graphically signiﬁcant stenosis (with or without intervention)
or positive ischemia testing during the unscheduled hospital-
ization. Chest pain in the absence of angiographic signiﬁcant
stenosis or negative ischemia testing was deﬁned as chest
pain without evidence of ischemia.
Statistical Analysis
Continuous variables are expressed as meansSD or medians
with 25th and 75th percentiles. P values were derived using t
tests in the former and Mann–Whitney U tests in the latter.
Categorical data are expressed as frequencies and percent-
ages and are compared using the v2 and Fischer’s exact tests.
For nested variables in lesion-level data, P values from general
and generalized mixed models were used. Poisson
Table 1. Reasons for Unplanned Rehospitalizations After
Primary PCI for STEMI (Including Multiple Events)
No. of RHs % of RHs
Unplanned cardiac rehospitalizations
Recurrent chest pain without evidence of
ischemia*
35 20.35
Recurrent chest pain with ischemia and
subsequent intervention†,‡
29 16.86
Ischemic events (myocardial infarction and/or
stent thrombosis)
29 16.86
Heart failure 28 16.28
Recurrent chest pain with ischemia with no
coronary intervention†
23 13.37
Tachyarrhythmias 11 6.40
Miscellany 9 5.23
Bradyarrhythmias 5 2.91
Pericarditis 3 1.74
Total 172 100
Unplanned noncardiac rehospitalizations
All bleeding 24 24.49
Miscellany§ 16 16.33
Infections (including sepsis) 14 14.29
Neoplasmsk 9 9.18
Abdominal pathologyk 8 8.16
Cerebrovascular event 8 8.16
Major vascular complication (excluding
bleeding)
4 4.08
Respiratory pathologyk 3 3.06
Urogenital pathologyk 3 3.06
Surgery: orthopedics 2 2.04
Surgery: abdominal 2 2.04
Surgery: miscellany 2 2.04
Acute renal failure (including
\decompensation of CKD)
2 2.04
Surgery: oncology (including biopsies) 1 1.02
Total 98 100
CKD indicates chronic kidney disease; PCI, percutaneous coronary intervention; RH,
rehospitalization; STEMI, ST-elevation myocardial infarction.
*Among 35 RHs, 8 included repeat coronary angiographies, 6 noninvasive stress tests,
and 2 noninvasive myocardial perfusion tests.
†
Stable or unstable angina.
‡
Percutaneous coronary intervention or coronary bypass graft surgery.
§
Accident, pupura, pemphigus, drug toxicity, allergies, gout, psychiatric disorder, or
vertigo.
k
Diagnosis or nonsurgical treatment.
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regressions, or negative binomial regressions in case of
overdispersion, were used to calculate rates of RH. To identify
risk factors, ﬁrst, missing values of these factors were
multiple-imputed using chained equations (40 data sets
created): body mass index, left ventricular ejection fraction,
SYNTAX score, hemoglobin, low-density lipoprotein (LDL),
renal insufﬁciency, hypertension, and history of malignancy;
note that also nonmissing information (age, sex, and cardiac
unplanned and noncardiac unplanned RH) were used in these
equations. Second, Poisson regressions or negative binomial
regressions were performed on each of these 40 data sets
and estimates were combined using Rubin’s rule. Third,
predictors included were all variables with a univariable effect
of P<0.05 on either patients with any cause of unplanned
cardiac RHs or patients with any cause of noncardiac RHs.
One single cause was determined for each RH, and predictors
analyses were done considering multiple RHs. Baseline and
procedural characteristics were compared at patient level (ie,
patients without versus with 1 or more RHs). Kaplan–Meier
curves for time to ﬁrst (unplanned cardiac or unplanned
noncardiac) RH were constructed. All P values shown are from
2-sided tests, and the level of statistical signiﬁcance was set
at 0.05. Analyses were performed using Stata software
(version 13; StataCorp LP, College Station, TX).
Results
Among the 1161 STEMI patients enrolled in the trial, a total of
1137 (97.9%) were eligible for this subanalysis. The patient
ﬂow chart is provided in Figure S1. Unplanned cardiac RHs
amounted to 172 episodes in 133 (11.7%) patients at 1 year,
and 98 episodes of unplanned noncardiac RHs were observed
in 79 (6.9%) patients at 1 year (Figure). Reasons for
unplanned cardiac and noncardiac RHs are presented in
Table 1. A total of 64 planned rehospitalizations were
identiﬁed and details are provided in Table S4.
Baseline and Procedural Characteristics
Baseline and procedural characteristics are summarized in
Table 2. Patients with at least 1 episode of unplanned cardiac
RH were older (62.5 versus 59.7 years; P=0.012) and had
similar comorbidities with the exception of higher prevalence
of renal failure (11.5% versus 6.3%; P=0.042) as compared
with patients without unplanned cardiac RH. Baseline LDL
cholesterol (3.1 versus 3.3 mmol/L; P=0.037) and left ven-
tricular ejection fraction were lower (45% versus 50%;
P=0.006), whereas Syntax MI score was higher (16 versus
13 points; P=0.002) in the unplanned cardiac RH cohort.
Patients readmitted for unplanned noncardiac reasons were
older (67.3 versus 59.7 years; P=0.001), more frequently
women (38% versus 18.7%; P=0.001), and had a lower body
mass index (25.7 versus 26.8 kg/m2; P=0.013) as compared
with patients without unplanned RHs. Comorbidities were more
frequent in patients with unplanned noncardiac RHs, including
higher prevalence of hypertension (59.5% versus 45.5%;
P=0.019), history of stroke or transient ischemic attack TIA
(8.9% versus2.7%;P=0.01), and renal failure (13.9% versus6.3%;
P=0.018). Moreover, unplanned noncardiac RH patients had a
lower baseline hemoglobin (13.7 versus 14.2 g/dL; P=0.001)
and LDL cholesterol (2.8 versus 3.3 mmol/L; P=0.002).
Reasons of Unplanned Rehospitalizations
According to Stent Assignment
We observed no signiﬁcant differences in the overall rate of
rehospitalization among patients assigned to bare-metal
stents when compared with those assigned to a biolimus-
eluting stent, except for recurrent chest pain with ischemia
Figure. Kaplan–Meier curves showing the incidence rate of unplanned cardiac and noncardiac rehospitalizations within 1 year.
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and subsequent intervention, which was more frequently the
reason for rehospitalization in patients treated by a bare-
metal stent (23.4% versus 9.0% [percentage of all RHs];
P=0.01). Moreover, when analyzing this reason of rehospital-
ization at a patient level, 4.4% of the patients assigned to the
bare-metal stent group exhibited 1 or more RHs versus 1.1%
in the biolimus-eluting stent group (incidence rate ratio, 3.1;
95% CI, 1.28–7.45). Detailed reasons for RH among stent
groups are provided in Table S5.
Predictors of Unplanned RHs
For the purpose of the multivariate analysis, we estimated the
rate of unplanned RHs within 1 year, accounting for multiple
events. The rate of unplanned cardiac RHs was 0.15 per
patient per year (95% CI, 0.13–0.18), whereas the rate of
unplanned noncardiac RHs was 0.09 per patient per year (95%
CI, 0.07–0.11). Predictors of 1-year unplanned cardiac RHs
after adjustment for baseline and procedural characteristics
are presented in Tables 3 and 4. Each 10% decrease in left
ventricular ejection fraction was associated with a 22%
increase in the rate of unplanned cardiac RHs (95% CI, 1.02–
1.46, P=0.03), and each 10-unit increase in Syntax-MI score
preceding primary PCI was associated with a 34% increase
(95% CI, 1.07–1.68; P=0.01). No other independent predictors
of unplanned cardiac RHs were identiﬁed.
Among patients who presented for unplanned noncardiac
RHs, age was the only independent predictor. A 10-year
increase of age was associated with a 43% increase in the rate
of unplanned noncardiac RHs (95% CI, 1.15–1.77; P=0.001).
Rates of Unplanned RHs at Country Level
Rates of unplanned cardiac and noncardiac RHs stratiﬁed by
countries are presented in Table 5. Among the 6 participating
countries, the rate of unplanned cardiac RHs per patient per year
was highest in Israel (0.40; 95% CI, 0.22–0.74) and Denmark
(0.26; 95% CI, 0.18–0.38) and lowest in Serbia (0.02; 95% CI,
0.01–0.07). Rates of RHs among The Netherlands, Switzerland,
and the United Kingdom were comparable. Regional rates of
readmission were more homogenous for unplanned noncardiac
RHs, ranging from 0.07 (95% CI, 0.04–0.16) in the United
Kingdom to 0.12 (95% CI 0.07–0.19) in Denmark. Finally, Serbia
presented the lowest rate of readmissions for unplanned
noncardiac causes (0.03; 95% CI, 0.01–0.07).
Discussion
The main ﬁndings of this analysis on the frequency, reasons,
and predictors of unplanned cardiac and noncardiac RHs post-
PCI in patients presenting with STEMI can be summarized as
follows:
1. Unplanned cardiac RHs at 1 year occurred in 12% of
patients representing approximately two thirds of all
unplanned RHs. When accounting for multiple events,
the annual RH rate per patient was 0.15.
2. The most common reason for unplanned cardiac RHs post-
PCI for STEMI was recurrent chest pain, which was
categorized by treating physicians as noncoronary origin in
one third of cases.
3. Syntax MI score and left ventricular ejection fraction were
independent predictors of unplanned cardiac RHs at
1 year and may aid in the identiﬁcation of patients at risk
for unplanned cardiac RHs.
4. Unplanned noncardiac RHs at 1 year occurred in 7% of
patients with bleeding as the leading cause and age
emerging as the only independent predictor identiﬁed.
The largest evidence available on RHs after acute MI is
derived from national data sets from the United States
including more than 500 000 patients, in which one ﬁfth
were rehospitalized within 30 days.8 Our lower rates of RH
are explained by the selective inclusion of unplanned RHs
only, as opposed to all-cause RHs,8 the lower risk of RHs
expected in a randomized, controlled trial with exclusion of
very-high-risk patients (eg, baseline critical condition, high
bleedings risk)9 and the previously reported lower rates of
readmission in European countries, when compared with the
United States.2 In the Assessment of Pexelizumab in Acute
Myocardial Infarction trial, which enrolled over 5000 STEMI
patients in 17 countries, the 30-day all-cause readmission
was 11.3%.2 In several countries, the odds of RHs where
less than half when compared with the United States,
including Italy, Germany, Canada, Portugal, and The Nether-
lands. In line with our ﬁndings, Switzerland was associated
with a numerically lower rate of RHs and Denmark with a
numerically higher rate. Further conﬁrmation of regional
variability stems from a recent study on 30-day all-cause
RHs post-PCI in Italy, with showed a rate as low as 4.7%.10
These differences may relate to patient characteristics and
local practices (ie, access site, referral habits). Given that
potential associated factors were not systematically
assessed, we may infer about other determinants, such as:
(1) accessibility to emergency department, and whether
patients visited ﬁrst a general practitioner or not; (2)
physicians counseling regarding chest pain recurrence and
conditions that should prompt consultation; and (3) differ-
ences in the threshold for readmission among countries.
Moreover, the possibility that true differences in the rate of
complications following primary percutaneous coronary
intervention for STEMI or that a misrepresentation of event
rates exist, may stimulate further research in this ﬁeld. Given
that comparable clinical outcomes (ie, major adverse cardiac
events) among countries were observed, true differences in
DOI: 10.1161/JAHA.117.005926 Journal of the American Heart Association 5
Rehospitalizations After STEMI Spitzer et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on O
ctober 18, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
complications other than major adverse cardiac events
following STEMI represents an unlikely explanation.
Reasons for Unplanned Cardiac and Noncardiac
RH
Our results indicate that recurrent chest pain is the most
common reason for unplanned RHs after PCI for STEMI,
amounting to two thirds of unplanned cardiac readmis-
sions within 1 year. Even though 70% of those RHs
justiﬁed a revascularization procedure or specialized care,
the remainders comprised a subgroup of patients in which
an opportunity to reduce rates of RHs exist. Chest pain
without evidence of ischemia (ie, noncoronary) comprises
a wide range of diagnoses with varying risk and need for
RH, from life-threatening conditions (eg, aortic dissection,
pulmonary embolism, and acute coronary syndrome) to
low-risk ailments (eg, musculoskeletal pain, gastroe-
sophageal reﬂux, and hypertensive cardiomyopathy).
Proper algorithms in emergency departments coupled
with noninvasive imaging techniques and laboratory tests
with high negative predictive value, could potentially avoid
unnecessary RHs, with the consequent reduction in health
costs. Conversely, the universal availability of such tests
might be restrained because of economic constraints. In
our study, 60% of patients were discharged based on
normal biomarkers and absence of electrocardiographic
changes, whereas 23% underwent coronary catheteriza-
tion. The relevance of recurrent chest pain without the
need for reintervention has been highlighted in PCI
registries,11,12 1 of which reported repeat revasculariza-
tions in less than 1 in 8 patients admitted with chest
pain, and suggested that low-risk chest pain may be
effectively evaluated in the outpatient or observational
settings. Patient counseling as to how to adequately react
to a pain episode may also translate in less cardiac RHs
attributed to chest discomfort.
We observed that bleeding was the most frequent
noncardiac cause of RHs and not unexpectedly in this
context, age emerged as an independent predictor in our
analysis. Other investigators have reported the frequency of
bleeding post-PCI for STEMI13,14; however, this study is the
ﬁrst to show bleeding as a leading cause. Acute coronary
syndrome patients are at a high risk for bleeding events
partly related to the administration of more-potent anti-
platelet therapy.15,16 Bleeding post-PCI is relevant consid-
ering its association with an increased risk of death at
long-term follow-up.17 Among patients undergoing PCI, the
most frequent bleeding site is the gastrointestinal tract.18
Noteworthy, increasing age, previous gastrointestinal bleed,
history of malignancy, smoking, and triple antithrombotic
therapy were reportedly independent predictors of
gastrointestinal bleeding.17 Upper gastrointestinal bleeding
appears preventable, in part, by administration of proton
pump inhibitors. Indeed, a recent study conﬁrmed a
signiﬁcant reduction in gastrointestinal bleeding events by
routine administration of proton pump blockers in PCI
patients receiving dual antiplatelet therapy.19 Furthermore,
the evaluation of bleeding risk by using dedicated scores
may aid in identifying patients in whom potent P2Y12
administration or a prolonged dual antiplatelet therapy
duration should be omitted.20,21
Predictors of Unplanned Cardiac and Noncardiac
RHs
Early RHs carry a signiﬁcant economic burden,12 and reducing
the number of RHs by improving quality of care speciﬁcally in
patients at high risk could lend to a better utilization of
resources. Notwithstanding, such an undertaking may turn
out complex. For instance, early physician follow-up have not
been associated with lower 30-day RH rates in patients
discharged after non-STEMI.22
Baseline and procedural characteristics associated with
unplanned RHs vary based on whether the cause of RH is
cardiac or noncardiac. Interestingly, comorbidities, such as
hypertension, previous stroke or transient ischemic attack,
history of malignancy, and anemia, were associated only with
unplanned noncardiac RHs, whereas lower left ventricular
systolic function and higher MI Syntax score were associated
only with unplanned cardiac RHs. A common characteristic of
patients being readmitted for both cardiac and noncardiac
reason was a signiﬁcantly lower LDL level measured before
initialization of statin therapy. Although not emerging as an
independent predictor, the association of low LDL and
unplanned RHs adds to previous observations including an
association between low LDL levels and increased total and
cardiovascular mortality in elderly23,24 and acutely diseased
individuals,25 as well as an increased risk of cancer.26 Based
on the reportedly consistent positive effect of LDL lowering by
statins in patients with coronary artery disease, it can be
assumed that a reverse causal relationship is responsible for
our observation.
Few independent predictors could be identiﬁed following
multivariate analysis. Age was the only one predicting
readmission for noncardiac reasons and left ventricular
function and Syntax MI score before revascularization. The
impact of ejection fraction on the prognosis of survivors of
acute MI is well established.27,28 Conversely, this is the ﬁrst
report on an association between the MI Syntax score with
unplanned cardiac RHs. A previous large-scale study found an
association on multivessel disease and readmissions, a
ﬁnding that was no longer present after the exclusion of
planned revascularization procedures, which were not
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Table 2. Baseline and Procedural Characteristics (Including First Events Only)
Overall No RHs
Unplanned
Cardiac RHs
Unplanned
Noncardiac RHs P Value P Value
N=1137 N=925 N=133 N=79
Cardiac vs
No RHs
Noncardiac vs
No RHs
Age, y 60.5 (52.1; 69.0) 59.7 (51.4; 67.8) 62.5 (53.3; 71.2) 67.3 (59.5; 77.5) 0.012 0.001
Female sex (%) 228 (20.1) 173 (18.7) 25 (18.8) 30 (38.0) 1.00 0.001
Body mass index, kg/m2 26.7 (24.3; 29.4) 26.8 (24.5; 29.5) 26.8 (24.0; 29.7) 25.7 (23.4; 28.7) 0.50 0.013
Heart rate, bpm 75.0 (65.0; 85.0) 75.0 (65.0; 85.0) 76.0 (64.0; 87.0) 75.0 (63.3; 84.3) 0.90 0.51
Family history of coronary
artery disease (%)
366 (32.8) 312 (34.1) 35 (27.1) 19 (26.0) 0.13 0.20
Diabetes mellitus (%) 168 (14.8) 138 (14.9) 21 (15.8) 9 (11.4) 0.80 0.51
Current smoker (%) 568 (50.5) 466 (51.0) 64 (48.1) 38 (48.7) 0.58 0.73
Hypertension (%) 529 (46.5) 421 (45.5) 61 (45.9) 47 (59.5) 1.00 0.02
Hypercholesterolemia* (%) 645 (57.0) 529 (57.5) 71 (53.8) 45 (57.0) 0.45 1.00
Previous CAD† (%) 79 (6.9) 66 (7.1) 9 (6.8) 4 (5.1) 1.00 0.65
Previous myocardial
infarction (%)
58 (5.1) 49 (5.3) 6 (4.5) 3 (3.8) 0.84 0.79
Previous PCl (%) 45 (4.0) 37 (4.0) 5 (3.8) 3 (3.8) 1.00 1.00
Previous CABG (%) 14 (1.2) 10 (1.1) 3 (2.3) 1 (1.3) 0.22 0.60
History of congestive heart
failure (%)
8 (0.7) 8 (0.9) 0 (0.0) 0 (0.0) 0.61 1.00
History of stroke or TIA (%) 35 (3.1) 25 (2.7) 3 (2.3) 7 (8.9) 1.00 0.010
History of malignancy (%) 53 (4.7) 41 (4.4) 5 (3.8) 7 (8.9) 1.00 0.09
Chronic obstructive lung
disease (%)
31 (2.7) 23 (2.5) 4 (3.0) 4 (5.1) 0.77 0.16
History of gastrointestinal
bleeding (%)
16 (1.4) 13 (1.4) 2 (1.5) 1 (1.3) 1.00 1.00
Clinical relevant valvular
disease (%)
3 (0.3) 2 (0.2) 0 (0.0) 1 (1.3) 1.00 0.22
Renal failure‡ (%) 83 (7.5) 57 (6.3) 15 (11.5) 11 (13.9) 0.04 0.02
Time from symptom onset to
balloon inflation, min
232.0 (162.0; 380.0) 228.0 (162.0; 372.0) 250.0 (161.0; 436.0) 246.0 (164.0; 416.0) 0.32 0.87
Resuscitation preceding
hospital arrival (%)
23 (2.0) 20 (2.2) 1 (0.8) 2 (2.5) 0.50 0.69
Killip III or IV (III or IV) (%) 14 (1.2) 10 (1.1) 3 (2.3) 1 (1.3) 0.22 0.60
Left ventricular function, % 50.0 (40.0; 60.0) 50.0 (42.0; 60.0) 45.0 (40.0; 55.0) 50.0 (44.3; 59.8) 0.006 0.64
Treatment of LAD (%) 469 (41.3) 377 (40.8) 63 (47.4) 29 (36.7) 0.16 0.55
Bifurcation treatment (%) 99 (8.7) 81 (8.8) 14 (10.5) 4 (5.1) 0.52 0.40
Multivessel treatment (%) 65 (5.7) 49 (5.3) 12 (9.0) 4 (5.1) 0.11 1.00
SYNTAX MI score, points 13.0 (9.0; 20.5) 13.0 (9.0; 20.0) 16.0 (10.5; 22.0) 12.0 (9.0; 20.0) 0.002 0.49
Length of stay at index
hospitalization, d
3.0 (2.0; 5.0) 3.0 (2.0; 5.0) 3.0 (2.0; 4.0) 3.0 (1.0; 4.0) 0.81 0.33
Postprocedural TIMI flow (%) 0.82 0.78
TIMI flow 0 to 2 51 (4.5) 42 (4.6) 5 (3.8) 4 (5.1) 0.82 0.78
TIMI flow 3 1084 (95.5) 881 (95.4) 128 (96.2) 75 (94.9) 0.82 0.78
Hemoglobin baseline, g/L 141.0 (132.0; 151.0) 142.0 (133.0; 152.0) 140.0 (130.0; 150.0) 137.0 (124.1; 147.3) 0.05 0.001
Thrombocytes baseline, g/L 234.0 (196.0; 273.0) 233.0 (196.0; 269.0) 233.5 (190.5; 290.5) 243.5 (190.5; 292.5) 0.49 0.17
Continued
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considered in our investigation. The Syntax score quantiﬁes
angiographic disease complexity and was shown to predict
patient- and device-oriented major adverse cardiac events
during follow-up in various clinical setting, including
STEMI.7,29 Although full revascularization was recommended
within the initial hospital stay, signiﬁcant lesions may
persisted and were treated conservatively, subsequently
leading to unplanned cardiac RH, an assumption that is
supported by a high contribution of repeat revascularization
procedures in previously untreated vessel segments. In the
absence of information of the completeness of revascular-
ization (ie, by assessing the residual Syntax score), we can
only speculate as to whether a more complete
Table 2. Continued
Overall No RHs
Unplanned
Cardiac RHs
Unplanned
Noncardiac RHs P Value P Value
N=1137 N=925 N=133 N=79
Cardiac vs
No RHs
Noncardiac vs
No RHs
LDL baseline, mmol/L 3.3 (2.6; 4.0) 3.3 (2.7; 4.0) 3.1 (2.5; 3.9) 2.8 (2.3; 3.7) 0.04 0.002
Country (%)
Serbia 167 (14.7) 158 (17.1) 4 (3.0) 5 (6.3)
Switzerland 547 (48.1) 447 (48.3) 58 (43.6) 42 (53.2)
United Kingdom 107 (9.4) 89 (9.6) 12 (9.0) 6 (7.6)
Denmark 170 (15.0) 119 (12.9) 35 (26.3) 16 (20.3)
Israel 47 (4.1) 30 (3.2) 14 (10.5) 3 (3.8)
The Netherlands 99 (8.7) 82 (8.9) 10 (7.5) 7 (8.9)
Results presented as median (25%, 75% percentile) or number (%). P values from the Kruskal–Wallis test or Fisher’s exact test. CABG indicates coronary artery bypass graft surgery; CAD,
coronary artery disease; LAD, left anterior descending artery; PCI, percutaneous coronary intervention; RH, rehospitalization; TIA, transient ischemic attack; TIMI, Thrombolysis In
Myocardial Infarction.
*Total cholesterol >5.0 mmol or 190 mg/dL or under treatment.
†
Includes previous MI, PCI, or CABG.
‡
Glomerular ﬁltration rate lower than 60 mL/min.
Table 3. Predictors of Unplanned Cardiac Rehospitalizations
Within 1 Year After PCI for STEMI (Including Multiple Events)
Rate 95% CI
Overall Rate: No. of
Rehospitalizations Per Patient Per Y 0.15 0.13 to 0.18
Predictors Rate Ratio P Value 95% CI
Age (per 10 y) 1.02 0.77 0.87 to 1.21
Left ventricular ejection
fraction (%) (per 10-unit
decrease)
1.22 0.03 1.02 to 1.46
MI Syntax score (per 10-unit
increase)
1.34 0.01 1.07 to 1.68
Hemoglobin baseline, g/L 1.00 0.53 0.98 to 1.01
LDL baseline, mmol/L 0.88 0.19 0.74 to 1.06
Renal failure
(GFR <60 mL/min)
1.18 0.61 0.63 to 2.21
Results from multivariable negative binomial regression with estimated rates of
rehospitalisation after multiple imputation of missing data using chained equations.
Estimates combined from 40 imputed data sets using Rubin’s rule. GFR indicates
glomerular inﬁltration rate; LDL, low-density lipoprotein; MI, myocardial infarction; PCI,
percutaneous coronary intervention; ST-elevation myocardial infarction.
Table 4. Predictors of Unplanned Noncardiac
Rehospitalizations Within 1 Year After PCI for STEMI
(Including Multiple Events)
Rate 95% CI
Overall Rate: No. of
Rehospitalizations Per
Patient Per Y 0.09 0.07 to 0.11
Predictors Rate Ratio P Value 95% CI
Age (per 10 y) 1.43 0.001 1.15 to 1.77
BMI (per 10 units) 0.86 0.59 0.51 to 1.47
Hemoglobin baseline, g/L 1.00 0.56 0.98 to 1.01
LDL baseline, mmol/L 0.83 0.11 0.65 to 1.05
Male sex 0.63 0.08 0.38 to 1.05
Hypertension 1.41 0.15 0.88 to 2.28
Renal failure
(GFR <60 mL/min)
0.98 0.96 0.50 to 1.95
History of malignancy 1.58 0.23 0.75 to 3.34
Results from multivariable negative binomial regression with estimated rates of
rehospitalisation after multiple imputation of missing data using chained equations.
Estimates combined from 40 imputed data sets using Rubin’s rule. BMI indicates body
mass index; GFR, glomerular inﬁltration rate; LDL, low-density lipoprotein; PCI,
percutaneous coronary intervention; ST-elevation myocardial infarction.
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revascularization at the index procedure or early after primary
PCI could attenuate unplanned cardiac RHs, and thereby safe
costs, as it was observed in previous studies.30 The total
number of rehospitalization events in this cohort throughout
1 year did not allow to investigate predictors for early
(<30 days) versus late (>30 days) rehospitalizations (cardiac
and noncardiac).
In this study, patients receiving biodegradable polymer
biolimus-eluting stents were compared with patients receiv-
ing bare-metal stents. The primary composite endpoint
of cardiac death, target vessel MI and target lesion
revascularization, occurred more frequently in patients
treated with bare-metal stents.31,32 Overall, we observed
no signiﬁcant difference in the rate of unplanned cardiac or
noncardiac rehospitalizations among groups. Nevertheless,
and in line with the main report of the trial, recurrent chest
pain with ischemia and subsequent intervention was more
frequently observed in the bare-metal stent group (4.4%
versus 1.1%).
Limitations
First, although COMFORTABLE AMI was designed as an all-
comers STEMI trial, 40% of patients presenting for STEMI
were not included in the trial, leading to an underestimation of
RH frequency, and the reasons and associated predictors of
unplanned RH potentially differ. This is supported by a report
that showed a higher rate of major adverse cardiovascular
events in patients excluded from the COMFORTABLE AMI
trial.9 Second, we did not record attendance to rehabilitation
after primary PCI, a variable that is hypothetically attenuating
the key end point of this study. Third, when multiple
diagnoses coexisted in a hospitalization, we deﬁned hierar-
chies that would allow categorization based on the cause of
admission. These hierarchies may not be applicable to other
settings. Fourth, because of the limited number of events and
study subjects, we did not include country of enrollment in the
predictors model. Finally, reasons for RH were ascertained by
review of severe adverse events listings and narratives;
consequently, adjudication was limited to the information
available.
Conclusion
Among STEMI patients undergoing primary PCI in the setting
of a randomized, clinical trial, unplanned cardiac RHs occurred
in 12%, with recurrent chest pain being the foremost reason.
Unplanned noncardiac RHs occurred in 7% with bleeding as
the leading cause. Left ventricular systolic function and
Syntax score were independent predictors of unplanned
cardiac RHs and identiﬁed patient subgroups in need for
improved secondary prevention.
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Table 5. Country-Speciﬁc Rates of Unplanned
Rehospitalizations (Including Multiple Events)
Rate 95% CI
Unplanned cardiac rehospitalizations (number per patient per y)
Overall 0.15 0.13 to 0.18
Serbia 0.02 0.01 to 0.07
Switzerland 0.14 0.11 to 0.18
United Kingdom 0.13 0.07 to 0.24
Denmark 0.26 0.18 to 0.38
Israel 0.40 0.22 to 0.74
The Netherlands 0.13 0.07 to 0.24
Unplanned noncardiac rehospitalizations (number per patient per y)
Overall 0.09 0.07 to 0.11
Serbia 0.03 0.01 to 0.07
Switzerland 0.09 0.07 to 0.12
United Kingdom 0.07 0.04 to 0.16
Denmark 0.12 0.07 to 0.19
Israel 0.11 0.04 to 0.28
The Netherlands 0.09 0.04 to 0.19
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Table S1. List of reasons for rehospitalizations 
Cardiac rehospitalizations 
Staged procedure or planned repeat angiography 
Recurrent chest pain without evidence of ischemia* 
Recurrent chest pain with ischemia but no intervention† 
Recurrent chest pain with ischemia and coronary intervention†,‡ 
Ischemic events (myocardial infarction and/or stent thrombosis) 
Bradyarrhythmias  
Tachyarrhythmias  
Planned implantation of a cardioverter defibrillator 
Heart failure  
Heart surgery due to valvular disease 
Pericarditis 
Other 
Non-cardiac rehospitalizations 
Cerebro-vascular event  
All bleeding  
Major vascular complication (excluding bleeding)  
Acute renal failure (including decompensation of chronic kidney disease) 
Respiratory pathology§ 
Abdominal pathology§ 
Urogenital pathology§ 
Neoplasms§ 
Infections (including sepsis) 
Surgery: vascular (aorta, peripheral arteries) 
Surgery: orthopedics 
Surgery: abdominal 
Surgery: urogenital 
Surgery: oncology (including biopsies) 
Surgery: other than the above  
Non-cardiac vascular death 
Non cardiovascular death 
Other॥ 
*Chest pain without confirmed source or manifestation of ischemia after diagnostic tests 
†Chest pain from cardiac origin with confirm source or manifestation of ischemia (stable or unstable angina) 
‡Percutaneous coronary intervention or coronary artery bypass graft surgery 
§Diagnosis or non-surgical treatment 
॥Accident, pupura, pemphigus, drug toxicity, allergies, gout, psychiatric disorder, or vertigo. 
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Table S2. Hierarchy applied when multiple reasons for unplanned rehospitalizations coexisted. 
Unplanned cardiac rehospitalizations 
Ischemic events (myocardial infarction and/or stent thrombosis) 
Surgical revascularization 
Heart surgery due to valvular disease 
Heart failure  
Recurrent chest pain with ischemia but no intervention 
Tachyarrhythmias  
Bradyarrhythmias  
Pericarditis 
Recurrent chest pain without evidence of ischemia 
Miscellany 
Unplanned non-cardiac rehospitalizations 
Cerebro-vascular event  
Cancer (diagnosis or treatment - not surgery) 
Respiratory pathology – not surgical  
Major vascular complication (excluding bleeding) 
Infections (including sepsis) 
Bleeding  
Acute renal failure (including decompensation of chronic kidney disease) 
Abdominal pathology - not surgical 
Non-cardiac surgery: cancer  
Non-cardiac surgery: abdominal 
Non-cardiac surgery: orthopedic 
Non-cardiac surgery: urogenital  
Urogenital pathology – not surgical  
Non-cardiac surgery: other than the above  
Miscellany 
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Table S3. Hierarchy applied when multiple reasons for planned rehospitalizations coexisted. 
Planned cardiac rehospitalizations 
Surgical revascularization 
Heart surgery due to valvular disease 
Percutaneous revascularization 
Planned implantation of a cardioverter defibrillator 
Tachyarrhythmias  
Bradyarrhythmias  
Miscellany 
Planned non-cardiac rehospitalizations 
Non-cardiac surgery: vascular (aorta, peripheral arteries)  
Cancer (diagnosis or treatment - not surgery) 
Respiratory pathology – not surgical  
Infections  
Non-cardiac surgery: cancer (including biopsies) 
Non-cardiac surgery: abdominal 
Non-cardiac surgery: orthopedic 
Non-cardiac surgery: urogenital  
Non-cardiac surgery: other than the above (including biopsies not related to cancer) 
Urogenital pathology – not surgical  
Miscellany 
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Table S4. Reasons for planned rehospitalizations after PCI for STEMI within one year 
Planned cardiac rehospitalizations  Nº of RHs % of RHs 
Percutaneous revascularization (any)  8 27.6 
Surgical revascularization   7 24.1 
Cardioverter defibrillator implantation  7 24.1 
Miscellany  5 17.2 
Bradyarrhythmias   1 3.5 
Heart surgery due to valvular disease  1 3.5 
Total  29 100 
Planned non-cardiac rehospitalizations  Nº of RHs % of RHs 
Surgery: oncology (including biopsies)  8 22.9 
Surgery: vascular  7 20.0 
Surgery: orthopedics  6 17.1 
Neoplasms   5 14.3 
Surgery: miscellany  5 14.3 
Surgery: urogenital  3 8.6 
Miscellany  1 2.9 
Total  35 100 
RH = rehospitalization 
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Table S5. Reasons for unplanned rehospitalizations after primary PCI for STEMI separate for patients randomized to bare-
metal stent BMS and to biolimus drug-eluting stent BES (including multiple events). 
  
Unplanned cardiac rehospitalizations  
BMS Nº 
of RHs 
(n=573) 
BMS %  
of RHs 
 
BES Nº  
of RHs 
(n=564) 
BES %  
of RHs 
 
p-value 
 
Recurrent chest pain without evidence of ischemia*   18 19.15 17 21.79 0.67  
Recurrent chest pain with ischemia and subsequent intervention†,‡   22 23.40 7 8.97 0.01  
Ischemic events (myocardial infarction and/or stent thrombosis)   17 18.09 12 15.38 0.64  
Heart failure   11 11.70 17 21.79 0.07  
Recurrent chest pain with ischemia with no coronary intervention†   9 9.57 14 17.95 0.11  
Tachyarrhythmias    6 6.38 5 6.41 0.99  
Miscellany   7 7.45 2 2.56 0.15  
Bradyarrhythmias   3 3.19 2 2.56 0.81  
Pericarditis   1 1.06 2 2.56 0.45  
Total   94 100 78 100   
Unplanned non-cardiac rehospitalizations  
BMS Nº 
of RHs 
(n=573) 
BMS %  
of RHs 
 
BES Nº  
of RHs 
(n=564) 
BES %  
of RHs 
 
p-value  
All bleeding    12 26.09 12 23.08 0.73  
Miscellany§   9 19.57 7 13.46 0.41  
Infections (including sepsis)   6 13.04 8 15.38 0.74  
Neoplasms॥   3 6.52 6 11.54 0.39  
Abdominal pathology॥   3 6.52 5 9.62 0.58  
Cerebro-vascular event    2 4.35 6 11.54 0.19  
Major vascular complication  (excluding bleeding)    3 6.52 1 1.92 0.25  
Respiratory pathology॥   1 2.17 2 3.85 0.63  
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Urogenital pathology॥   2 4.35 1 1.92 0.49  
Surgery: orthopedics   1 2.17 1 1.92 0.93  
Surgery: abdominal   1 2.17 1 1.92 0.93  
Surgery: miscellany    2 4.35 0 0.00 0.13  
Acute renal failure (including decompensation of CKD)   1 2.17 1 1.92 0.93  
Surgery: oncology (including biopsies)   0 0.00 1 1.92 0.34  
Total   46 100 52 100   
RH = rehospitalization; CKD = chronic kidney disease; BMS = bare-metal stent; BES: biolimus-
eluting stent 
p-values are derived using the Chi-Square Test for each reason relative to total hospitalizations. 
*Among 35 RH, 8 included repeat coronary angiographies, 6 non-invasive stress tests, and 2 non-
invasive myocardial perfusion tests. 
†Stable or unstable angina. 
‡Percutaneous coronary intervention or coronary bypass graft surgery. 
§Accident, pupura, pemphigus, drug toxicity, allergies, gout, psychiatric disorder, or vertigo. 
॥Diagnosis or non-surgical treatment. 
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Figure S1. Patient flowchart 
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